Loading...
Loading...
Thursday, Virax Biolabs Group Limited (NASDAQ: VRAX) announced it is launching ‘ImmuneSelect' within the ViraxImmune T-Cell diagnostic platform for research-use-only (RUO) at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 Congress.
"We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs."The launch marks a significant milestone for Virax, as it brings us a step closer to commercializing ViraxImmune as a full in-Vitro Diagnostic product." ImmuneSelect is the company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity. ImmuneSelect is developed to evaluate T-Cell driven immunity and to aid in the understanding and early characterization of symptoms associated with post-viral syndromes, including Long COVID.Price Action: VRAX shares closed at $0.66 on Wednesday.
Loading...
Loading...
Posted In: BiotechNewsesportiva bet:Health Careesportiva bet:Top Storiesesportiva bet:Market-Moving Exclusivesesportiva bet:ExclusivesGeneralBriefs
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.esportiva bet:Join Now: Free!
Already a member?Sign in